Todas las investigaciones
Activo, no reclutandoFASE2INTERVENCIONISTA

CM-101 in PSC Patients -The SPRING Study

The SPRING Study is a research project investigating a new medicine, CM-101, for people living with Primary Sclerosing Cholangitis (PSC). PSC is a chronic liver disease that can lead to serious health problems. The study wants to find out if CM-101 is safe to use, how people tolerate it, and if it could help manage their PSC. Around 68 adults with PSC will take part, some receiving CM-101 and others a dummy drug (placebo). This research is important to potentially find new and better ways to treat PSC. Participants will be closely monitored by doctors throughout the study.

De un vistazo

Estado
Activo, no reclutando
Fase
FASE2
Patrocinador
ChemomAb Ltd.
Objetivo de inscripción
68
Inicio
01 Oct 2020
Estimación de finalización
01 Sep 2025

¿De qué trata este estudio?

This study, known as The SPRING Study, is focused on a liver condition called Primary Sclerosing Cholangitis (PSC). PSC is a disease that affects the bile ducts in the liver, which are tiny tubes that carry digestive fluid. Over time, these ducts can become inflamed and scarred, leading to serious liver damage. Currently, there isn't a cure for PSC, so finding new treatments is really important.

Researchers are investigating a new medication called CM-101. This medicine is a type of antibody, which are special proteins that target specific things in the body. In this case, CM-101 is designed to work against a particular protein called CCL24, which is thought to play a role in PSC.

The main goals of The SPRING Study are to see if CM-101 is safe for people with PSC, how well they tolerate it (meaning if they have uncomfortable side effects), and if it shows any signs of improving their condition. This is a "Phase 2" study, which means it builds on earlier research and aims to get a better understanding of the drug's effects in a larger group of patients. If CM-101 proves promising in this study, it could move on to further research stages.

Puntos clave

  • The study is for adults with Primary Sclerosing Cholangitis (PSC).
  • It's testing a new medication called CM-101.
  • The main goals are to check safety and if the drug helps PSC.
  • Participation involves regular clinic visits and medication doses.
  • You might receive CM-101 or a placebo during the first part.
  • Puedes dejar de participar en cualquier momento.

¿Quién puede ser elegible?

To join The SPRING Study, you need to be an adult between 18 and 75 years old and have been diagnosed with PSC for at least 24 weeks. Your doctor must also agree that there are no serious concerns about another liver condition called cholangiocarcinoma (a type of bile duct cancer). Additionally, a specific liver enzyme in your blood, called Alkaline Phosphatase (ALP), needs to be above a certain level during screening.

If you're already taking medication for PSC, like ursodeoxycholic acid (UDCA), you need to have been on a steady dose for at least 3 months before starting the study. If you also have inflammatory bowel disease (like ulcerative colitis or Crohn's disease), it needs to be well-controlled. For women who could become pregnant, it's essential to use effective contraception throughout the study and for a period afterwards. Men must also use barrier contraception if they are not vasectomized.

Some things would prevent you from joining. For example, if you have another type of sclerosing cholangitis, a different serious liver disease, or a condition where your immune system attacks your liver (called autoimmune hepatitis), you wouldn't be able to participate. The medical team will check all these details carefully to make sure the study is right and safe for you.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. ¿Tienes entre 18 y 75 años?
  2. Have you been diagnosed with PSC for at least 6 months?
  3. Is your ALP blood test level higher than normal?
  4. If taking PSC medication (like UDCA), has your dose been stable for 3 months?
  5. If you have inflammatory bowel disease, is it well-controlled?
  6. Are you able to use effective contraception if needed?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you decide to take part in The SPRING Study, it will involve several stages. First, there's a screening period to check if you're suitable. Then, for the main part of the study, you'll receive the study drug (CM-101) or a placebo (a dummy drug). This will happen through an injection once every three weeks, for a total of five doses over 15 weeks. You won't know if you're getting CM-101 or the placebo, and neither will your local doctor.

After these 15 weeks, you might be able to continue receiving CM-101 in an 'open-label' period, where everyone knows they are getting the active drug. This involves another 11 doses over 33 weeks. So, you could be taking part for up to 48 weeks receiving the study drug. Throughout the study, you'll have regular visits to the clinic for check-ups, blood tests, and to make sure you're doing well. There will also be follow-up calls and visits after you finish taking the medication to monitor your health. The total time for follow-up could extend to about 60 weeks from when you first start.

Riesgos y beneficios potenciales

Taking part in any clinical study has potential benefits and risks. You might benefit from closer monitoring of your PSC and access to a new treatment (CM-101) before it's widely available. However, there's also a chance you could receive the placebo and not the active drug. As CM-101 is an experimental medication, there could be side effects that are not yet fully known. The research team will explain all known risks and monitor you very closely for any issues. It's important to remember that you are a volunteer and can choose to leave the study at any time, for any reason, without affecting your usual medical care.

Locations (33)

  • Scripps Clinic Torrey Pines - site P83
    Código postal verificado
    La Jolla, Estados Unidos
  • UC Davis Health System - Midtown Ambulatory Care Center - site P79
    Código postal verificado
    Sacramento, United States
  • Northwestern University - site P77
    Código postal verificado
    Chicago, Estados Unidos
  • Massachusetts General Hospital - site P95
    Código postal verificado
    Boston, Estados Unidos
  • Harvard Medical School - Beth Israel Deaconess Medical Center (BIDMC) - Liver Center - site P81
    Código postal verificado
    Boston, Estados Unidos
  • Gastro One - GI Diagnostic and Therapeutic Endoscopy Center - 1310 Wolf Park - site P82
    Código postal verificado
    Germantown, United States
  • Methodist Dallas Medical Center - site P72
    Código postal verificado
    Dallas, United States
  • Virginia Commonwealth - site P94
    Código postal verificado
    Richmond, Estados Unidos
  • Klinikum der Johann Wolfgang Goethe-Universitaet - site P42
    Código postal verificado
    Frankfurt am Main, Germany
  • Universitätsklinikum Hamburg-Eppendorf (UKE) - site P47
    Código postal verificado
    Hamburgo, Alemania
  • Medizinische Hochschule Hannover (MHH) - site P41
    Código postal verificado
    Hanóver, Alemania
  • Soroka MC - site P23
    Código postal verificado
    Beersheba, Israel

Preguntas comunes

What is Primary Sclerosing Cholangitis (PSC)?

PSC is a long-term liver disease that causes inflammation and scarring in the bile ducts, which are tubes that carry bile from your liver. This can lead to liver damage over time.

What is CM-101?

CM-101 is a new, experimental medication being tested in this study. It's designed to target a specific protein in the body that researchers believe is involved in PSC.

¿Qué es un 'placebo'?

A placebo is adummy treatment that looks exactly like the study drug but doesn't contain any active medicine. It helps researchers compare the effects of the new drug against no treatment.

¿Cuánto tiempo estaré en el estudio?

You could be in the study for up to 48 weeks receiving treatment, plus additional follow-up periods, possibly extending to around 60 weeks in total.

Will I know if I'm getting the real drug or the placebo?

During the first part of the study, neither you nor your doctor will know if you're receiving CM-101 or the placebo. This is called 'double-blind' and helps ensure fair results. Later, you might have the option to receive the active drug open-label.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.